Jones Financial Companies
CADL icon

Jones Financial Companies’s Candel Therapeutics CADL Stock Holding History

Jones Financial Companies’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.99K Hold
1,020
– – ﹤0.01% 3789
2026
Q1 		$4.91K Hold
1,020
– – ﹤0.01% 3852
2025
Q4 		$5.76K Sell
1,020
-310
-23% -$1.67K ﹤0.01% 3443
2025
Q3 		$7.37K Buy
1,330
+874
+192% +$5.05K ﹤0.01% 3199
2025
Q2 		$2.23K Hold
456
– – ﹤0.01% 3437
2025
Q1 		$2.71K Buy
+456
New +$3.73K ﹤0.01% 3173

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jones Financial Companies's CADL Position: Q2 2026 in Review

Jones Financial Companies held its Candel Therapeutics (CADL) position steady in Q2 2026 at 1,020 shares worth $9.99K. The position accounts for ﹤0.01% of the portfolio, ranked #3789.

Jones Financial Companies first reported a position in CADL in Q1 2025 and has held it in 6 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Jones Financial Companies held 1,020 shares of Candel Therapeutics worth $9.99K as of Q2 2026.
  • Jones Financial Companies left its Candel Therapeutics share count unchanged in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #3789 holding.
  • Jones Financial Companies first reported a position in Candel Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.